Anti-CD30 Antibodies for Hodgkin Lymphoma

Foyil, Kelley V.; Bartlett, Nancy L.

doi:10.1007/s11899-010-0053-y

Cited by 48 publications

(50 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This trial was reported in 1992 and no further trials were reported. Because of the similar antigen of BER-H2-Sap6 and Ki-4.dgA, their performance has been compared [191] …”

Section: Ber-h2-sap6mentioning

confidence: 99%

Antibody-Based Immunotoxins for the Treatment of Cancer

Becker

Benhar

2012

Antibodies

View full text Add to dashboard Cite

Antibody-based immunotoxins comprise an important group in targeted cancer therapeutics. These chimeric proteins are a form of biological guided missiles that combine a targeting moiety with a potent effector molecule. The targeting moiety is mostly a monoclonal antibody (MAb) or a recombinant antibody-based fragment that confers target specificity to the immunotoxin. The effector domain is a potent protein toxin of bacterial or plant origin, which, following binding to the target cells, undergoes internalization and causes cell death. Over time and following research progression, immunotoxins become better fitted to their purpose, losing immunogenic fragments and non-specific targeting moieties. Many immunotoxins have gone through clinical evaluation. Some of these have been shown to be active and work is progressing with them in the form of further clinical trials. Others, mostly developed in the previous century, failed to generate a response in patients, or even caused undesired side effects. This article reviews the antibody and protein-toxin based immunotoxins that were clinically evaluated up to the present day.

show abstract

“…This trial was reported in 1992 and no further trials were reported. Because of the similar antigen of BER-H2-Sap6 and Ki-4.dgA, their performance has been compared [191] …”

Section: Ber-h2-sap6mentioning

confidence: 99%

Antibody-Based Immunotoxins for the Treatment of Cancer

Becker

Benhar

2012

Antibodies

View full text Add to dashboard Cite

show abstract

“…3,4 Different companies use different strategies: Roche (Basel, Switzerland), in cooperation with Glycart (Schlieren, Switzerland), has developed an improved, glyco-engineered CD20 antibody, termed GA101. 5 Two other antibodies directed to the lymphoma-associated antigens CD19 (XmAb5574) 6,7 and CD30 (XmAb2513), 8 developed by Xencor (Monrovia, CA, USA), carry the amino-acid exchanges S239D and I332E (SDIE modification). All these antibodies were reported to exert markedly enhanced ADCC.…”

Section: Introductionmentioning

confidence: 99%

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia

et al. 2012

View full text Add to dashboard Cite

The therapeutic efficacy of humanized or chimeric second-generation antitumor antibodies is clearly established, but often limited. In recent years, defined modifications of the glycosylation pattern or the amino-acid sequence of the human immunoglobulin G1 Fc part have resulted in the development of third-generation antibodies with improved capability to recruit Fc receptor-bearing effector cells. The first antibodies of this kind, currently evaluated in early clinical trials, are directed against lymphoma-associated antigens. Fc-engineered antibodies targeting myeloid leukemia are not yet available. We here report on the generation and preclinical characterization of an Fc-optimized antibody directed to the FMS-related tyrosine kinase 3 (FLT3), an antigen expressed on the leukemic blasts of all investigated patients with acute myeloid leukemia (AML). This antibody, termed 4G8SDIEM, mediated markedly enhanced cellular cytotoxicity against FLT3-expressing cell lines as well as blasts of AML patients. FLT3 expression levels on AML cells varied between 300 and 4600 molecules/cell and, in most cases, were substantially higher than those detected on normal hematopoietic precursor cells and dendritic cells (approximately 300 molecules/cell). Antibody-mediated cytotoxicity against these normal cells was not detectable. 4G8SDIEM has been produced in pharmaceutical quality in a university-owned production unit and is currently used for the treatment of leukemia patients.

show abstract

“…One Newer generation of anti-CD30 antibodies with enhanced Fc receptor-antibody activity (Medarex, MDX-1401 ) and with antibody-drug conjugates are currently under study (Foyil and Bartlett 2010).…”

Section: Antibody/receptor Therapymentioning

confidence: 99%